AEGON ASSET MANAGEMENT UK Plc Purchases 777 Shares of Eli Lilly and Company $LLY

Key Points

• AEGON Asset Management UK increased its Eli Lilly stake by 777 shares (1%) in the third quarter, bringing its holdings to 81,803 shares valued at about $94.7 million.
• Institutional investors own 82.53% of Eli Lilly shares; several major holders, including BlackRock and State Street, also increased their positions.
• Analysts’ average rating is “Moderate Buy,” with an average price target of $1,416.64. Eli Lilly also reported quarterly earnings and revenue above analyst expectations, with revenue up 38.6% year over year.

AEGON ASSET MANAGEMENT UK Plc raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 81,803 shares of the company's stock after purchasing an additional 777 shares during the period. Eli Lilly and Company accounts for approximately 1.0% of AEGON ASSET MANAGEMENT UK Plc's portfolio, making the stock its 25th largest position. AEGON ASSET MANAGEMENT UK Plc's holdings in Eli Lilly and Company were worth $94,653,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the period. State Street Corp boosted its position in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the last quarter. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the second quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after acquiring an additional 137,364 shares during the period. Finally, Jennison Associates LLC grew its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after acquiring an additional 400,538 shares during the period. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an "overweight" rating in a research note on Friday, October 30th. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research note on Friday, October 30th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a "buy" rating in a research note on Monday. Finally, TD Cowen restated a "buy" rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,416.64.

Eli Lilly and Company Stock Up 4.4%

Shares of NYSE:LLY opened at $1,413.22 on Tuesday. The business's 50 day simple moving average is $1,220.13 and its two-hundred day simple moving average is $1,102.83. The firm has a market cap of $1.33 trillion, a P/E ratio of 44.38, a PEG ratio of 1.77 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,453.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company's revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter last year, the firm posted $7.02 earnings per share. As a group, research analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.